Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Cristina Gervasoni and Agostino Riva.
Cristina Gervasoni
Connection Strength
2.585
Agostino Riva
  1. Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020 07; 157:104826.
    View in: PubMed
    Score: 0.878
  2. The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol. 2017 Jun; 73(6):789-790.
    View in: PubMed
    Score: 0.707
  3. Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clin Infect Dis. 2020 11 19; 71(16):2276-2278.
    View in: PubMed
    Score: 0.229
  4. Remitting infections due to community-acquired Panton-Valentine leukocidin-producing Staphylococcus aureus in the Milan area. J Infect Public Health. 2018 Mar - Apr; 11(2):255-259.
    View in: PubMed
    Score: 0.183
  5. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother. 2017 06 01; 72(6):1842-1844.
    View in: PubMed
    Score: 0.180
  6. Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metab Pers Ther. 2017 05 24; 32(2):115-117.
    View in: PubMed
    Score: 0.179
  7. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017; 22(4):353-356.
    View in: PubMed
    Score: 0.174
  8. Does lopinavir really inhibit SARS-CoV-2? Pharmacol Res. 2020 08; 158:104898.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.